Arbutus Biopharma (ABUS) 10-K2017 FY Annual report

Filed: 16 Mar 18, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: Acknowledgment, Agency, ALNY, amalgamated, analyzing, appeal, appealed, ARB, Article, Authorisation, BComm, billion, binding, Biophrama, Bryce, Bulletin, CA, Characterization, checkpoint, closeout, closer, closure, Codification, comparison, correlated, CPA, criminal, curtailment, cybersecurity, deeper, destabilizer, destabilizing, diminish, diminished, disgorgement, display, divided, driven, drop, durable, EMA, essential, estate, ethical, feature, fundamental, fundamentally, Gritstone, ideal, immunotherapy, imprisonment, intact, interface, jointly, judge, Koert, KPMG, largest, leave, Lockup, lt, MAD, mandate, mandatorily, mandatory, McElhaugh, Medicaid, mg, MOA, Moderna, Murphy, na, neoantigen, Nsdaq, onward, organizational, orphan, oversaw, owner, passed, pathway, payor, PCAOB, pegylated, physical, PK, posed, prescription, preservation, proforma, qualitative, quantitative, reassessment, recommendation, redemption, relaxing, Relay, relocation, remeasured, repeat, restraining, reverse, SAB, secondary, SOC, sofosbuvir, spin, steering, stepwise, stop, striking, structure, structuring, TCJA, TDF, timeline, tranche, turnover, undetectable, vaccine, VandenEnden, Vaughan

Removed: acetaldehyde, acid, adrenocortical, Africa, aldehyde, ALDH, animal, antagonism, Aradigm, arm, arrest, auditing, Aug, batch, BMS, broader, budget, cardiovascular, cholesterol, Chylomicronemia, Ciprofloxacin, compensate, concept, concurrent, consortium, contingently, death, deducted, dehydrogenase, designation, disulfiram, documented, Doylestown, Easton, elevated, Emerging, enrolling, enzyme, EP, escalation, ethanol, evaluable, existence, exploring, Familial, fatty, fcs, formulated, function, gastrointestinal, hereditary, higher, HTG, humanized, hypercholesterolemia, hyperlipidemia, induce, ineffective, influenza, inhibiting, insulin, integrate, interfering, inventory, invoiced, ISARIC, iterative, Japan, label, lamivudine, legacy, Leone, lesser, lethal, line, log, maximize, medically, metabolism, mixed, mode, multivalent, neuroendocrine, NUC, nucleotide, outbreak, overview, physiological, poor, poorer, population, prevalence, progression, proliferation, prolonged, proof, protocol, published, pulmonary, pursued, ranged, RECIST, replicate, representative, residual, Respiratory, rest, revalue, ribonucleic, Road, robust, science, sector, shared, Sierra, silence, silencing, Society, solid, stable, steroid, strain, subset, Syndrome, Transformational, triglyceride, Tuesday, tumor, unrecovered, utilized, validate, validation, viable, Voucher, week, Wellcome

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated ABUS transcripts

ABUS similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Arbutus Biopharma Corporation (the “Company”) on Form 10-K for the year ended December 31, 2017, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I Mark J. Murray, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:


1.	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and


2.	The information contained in the Report fairly represents, in all material respects, the financial condition and results of the operations of the Company.

Date: March 15, 2018



			/s/ Mark J. Murray
	Name:		Mark J. Murray
	Title:		President and Chief Executive Officer